Education
About Us
Working with TipRanks
Follow Us
Cellectar Biosciences (CLRB)
NASDAQ:CLRB
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.18Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: 11.54%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and a substantial reduction in net loss, suggesting strong operational improvements. However, financial constraints and reliance on strategic partnerships indicate challenges ahead.Company Guidance
During the Cellectar Biosciences first quarter 2025 conference call, the company presented significant progress in its clinical development pipeline, notably with iopofosine I 131 for Waldenstrom's Macroglobulinemia (WM). The Phase 2 CLOVER WaM trial of iopofosine I 131 demonstrated a major response rate of 58.2% in the overall patient population and 59% in post-BTKI patients, indicating substantial efficacy compared to the typical 10-20% response rates of existing treatments. Cellectar is pursuing accelerated approval from the FDA and conditional approval from the EMA, with a Phase 3 trial planned to enroll about 100 patients per arm. Financially, the company reported a net loss of $6.6 million ($0.14 per share) for Q1 2025, a significant improvement from the $26.6 million ($0.91 per share) loss in Q1 2024, with cash reserves of $13.9 million expected to fund operations into Q4 2025. The company is also exploring strategic alternatives to maximize shareholder value, including potential mergers or acquisitions.Progress in iopofosine I 131 for Waldenstrom's Macroglobulinemia
Cellectar has made significant progress with iopofosine I 131, demonstrating unique efficacy and safety in Phase 2 trials for Waldenstrom's Macroglobulinemia (WM). Meetings with the FDA regarding accelerated approval and seeking EMA guidance for conditional approval are underway.
Decreased Research and Development Expenses
Research and development expenses decreased from $7.1 million in Q1 2024 to $3.4 million in Q1 2025, largely due to reduced patient follow-up activities and personnel costs.
Net Loss Reduction
Net loss for Q1 2025 was $6.6 million or $0.14 per share, significantly reduced from $26.6 million or $0.91 per share in Q1 2024.
Strong Pipeline Development
Cellectar's pipeline includes promising radiopharmaceutical candidates for pancreatic cancer and triple negative breast cancer, with ongoing studies and preparation for new trials.
CLRB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLRB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $0.26 | $0.24 | -7.69% |
Mar 13, 2025 | $0.32 | $0.30 | -6.25% |
Nov 18, 2024 | $1.86 | $1.77 | -4.84% |
Aug 13, 2024 | $1.86 | $2.02 | +8.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cellectar Biosciences (CLRB) report earnings?
Cellectar Biosciences (CLRB) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Cellectar Biosciences (CLRB) earnings time?
Cellectar Biosciences (CLRB) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLRB EPS forecast?
CLRB EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.